The European Medicines Agency (EMA) has started testing a corona drug from the pharmaceutical company Roche and its partner Regeneron. The EMA Committee for Medicinal Products for Human Use is investigating REGN-COV2, a combination of two antibodies, the agency said on Monday.
–
The drug, which was jointly developed by the US manufacturer Regeneron and Roche, is said to have been used last year to treat the Covid infection of then US President Donald Trump.
According to the EMA, the effectiveness test is carried out as part of a so-called rolling review process. Experts evaluate data from studies, even if these tests have not yet been completed and no application for approval has yet been submitted. The approval process can be shortened in this way.
Attention – limited entry! Registration is only possible until February 4, 2021, 3 p.m.
–According to the EMA, a study suggests the drug may reduce the amount of coronaviruses present in the blood. But it is still too early to draw conclusions about the relationship between benefits and risks. In the USA, REGN-COV2 has an emergency approval from the FDA. It is still open whether the EMA will recommend approval for Europe to the EU Commission.
At the end of January, the German Health Minister Spahn announced the purchase of 200,000 doses of two antibody drugs for corona treatment for around 400 million euros. They are to be used initially in university clinics for high-risk patients in the early phase.
In addition to REGN-COV2, the ministry ordered a drug from the US pharmaceutical company Eli Lilly, which also contains so-called monoclonal antibodies. They are manufactured in the laboratory and should be able to put the virus out of action after infection.
THE SHAREHOLDER remains confident about the long-term development of Roche shares. The pipeline is very strong and could hold some news, especially in the coming year. Roche is also a reliable dividend payer. The rate of return is currently 3.0 percent. From a technical chart perspective, it would be important to regain the 200-day line quickly. The jump over the 200-day line would also be important for the shares of US partner Regeneron. THE SHAREHOLDER expects a lot from this value in the future.
–
Regeneron Pharmaceuticals
(WKN: 881535)
–
–
(With material from dpa-AFX)
– .
